share_log

SpringWorks Therapeutics (NASDAQ:SWTX) PT Raised to $103.00 at HC Wainwright

Defense World ·  Sep 13, 2022 04:23

SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) had its price target hoisted by HC Wainwright from $94.00 to $103.00 in a report published on Monday morning, The Fly reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research note on Monday, June 20th. The Goldman Sachs Group dropped their target price on SpringWorks Therapeutics from $92.00 to $76.00 and set a buy rating for the company in a research note on Tuesday, May 24th.

Get SpringWorks Therapeutics alerts:

SpringWorks Therapeutics Stock Up 12.8 %

NASDAQ SWTX opened at $31.98 on Monday. SpringWorks Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $77.70. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -6.86 and a beta of 0.85. The business has a fifty day moving average of $28.97 and a 200-day moving average of $37.75.

SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). SpringWorks Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.97) earnings per share. As a group, analysts anticipate that SpringWorks Therapeutics will post -5.46 EPS for the current year.

Institutional Investors Weigh In On SpringWorks Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Amundi purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $77,000. Legal & General Group Plc grew its position in SpringWorks Therapeutics by 30.6% during the second quarter. Legal & General Group Plc now owns 28,429 shares of the company's stock valued at $700,000 after acquiring an additional 6,660 shares during the period. ExodusPoint Capital Management LP purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $663,000. Walleye Capital LLC purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $1,624,000. Finally, Goldman Sachs Group Inc. grew its position in SpringWorks Therapeutics by 21.5% during the second quarter. Goldman Sachs Group Inc. now owns 270,687 shares of the company's stock valued at $6,665,000 after acquiring an additional 47,978 shares during the period.

About SpringWorks Therapeutics

(Get Rating)

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Featured Articles

  • Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
  • Do These Dividend Achievers Deserve A Place In Your Portfolio?
  • Darden Restaurants Takes the Low Road Against Inflation
  • Why These 3 Stocks Are Off to Hot September Starts
  • Inflation Doesn't Differentiate, But it's Impact Does
  • 3 Downgraded Must-Have Stocks To Put On Your Watchlist

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment